Drug Barzolvolimab Shows Sustained Angioedema Relief in CSU Patients Seven Months After Dosing
Phase 2 data presented at a medical meeting found that barzolvolimab produced rapid and lasting reductions in angioedema for patients with antihistamine-refractory chronic spontaneous urticaria. Improvements began within one week and continued through 52 weeks of treatment, remaining evident 24 weeks after the final dose.
Long-term results from a Phase 2 study of barzolvolimab showed rapid, significant, and durable improvements in angioedema among patients with moderate to severe chronic spontaneous urticaria who had not responded to antihistamines. Relief from angioedema symptoms began as early as Week 1 and deepened over 52 weeks of treatment.
Improvements remained evident seven months after the final dose, at Week 76. The same statement noted that angioedema contributes to painful swelling and reduced quality of life for many patients with the condition. A company official said the Phase 2b trial data confirmed that treatment produced rapid, significant, and durable improvements in angioedema.
